 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Internal Medicine Pharmacy Practice Resident, College of Pharmacy, University of Oklahoma, Oklahoma City, OK
PharmD Student, College of Pharmacy, University of Oklahoma
Assistant Professor, College of Pharmacy, University of Oklahoma
Reprints: Dr. Vesta, College of Pharmacy, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190-5040, fax 405/271-6430, Kimi-Vesta{at}ouhsc.edu
OBJECTIVE: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.
DATA SOURCES: Literature was accessed through MEDLINE (1966-May 2006), Current Contents Clinical Medicine (1998-May 2006), and The Cochrane Library Database (1st quarter 2006) using the terms cilomilast, Ariflo, and SB 207 499. Reference lists from retrieved articles and information from the manufacturer were manually reviewed.
STUDY SELECTION AND DATA EXTRACTION: All clinical trials evaluating cilomilast and published in English were included in this review. In addition, articles evaluating the pharmacology, pharmacokinetics, and safety of cilomilast in humans were reviewed.
DATA SYNTHESIS: Cilomilast is a second-generation PDE4 inhibitor with antiinflammatory effects that target bronchoconstriction, mucus hypersecretion, and airway remodeling associated with chronic obstructive pulmonary disease (COPD). Selective PDE4 inhibition is proposed to maximize the antiinflammatory effects of PDE inhibition while minimizing the adverse effects of nonselective agents. To date, 4 clinical trials have evaluated the efficacy of cilomilast and demonstrated improvement in lung function (forced expiratory volume in 1 second) and quality of life and reduction in the occurrence of COPD exacerbations compared with placebo. Cilomilast is generally well tolerated, with adverse effects being overall mild and self-limiting.
CONCLUSIONS: COPD is a progressive disease, and available treatment options provide limited efficacy. Given its unique mechanism of action and improved adverse effect profile compared with previous agents, cilomilast may have a promising role for the management of COPD.
Key Words: chronic obstructive pulmonary disease, cilomilast, selective phosphodiesterase-4 inhibitor
Published Online, September 19, 2006. www.theannals.com, DOI 10.1345/aph.1H049
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE
UNIVERSAL PROGRAM NUMBER: 407-000-06-025-H01
This article has been cited by other articles:
|
|
 |
|
  K. Woyda, S. Koebrich, I. Reiss, S. Rudloff, S. S. Pullamsetti, A. Ruhlmann, N. Weissmann, H. A. Ghofrani, A. Gunther, W. Seeger, et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia Eur. Respir. J., April 1, 2009; 33(4): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sato, Y. Hoshino, T. Hara, S. Muro, H. Nakamura, M. Mishima, and J. Yodoi Thioredoxin-1 Ameliorates Cigarette Smoke-Induced Lung Inflammation and Emphysema in Mice J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 380 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
